Sesen Bio, Inc.
Sesen Bio, Inc. (SESN) Stock Forecast & Analyst Price Target
Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.
sesn · stock forecast · 8 analysts (3M) · FMP · updated Dec 4, 2023
Analyst Rating & Consensus
Based on 8 Wall Street analysts in the past 3 months
Buy
8 analysts
consensus
Rating Breakdown
12-Month Price Target
High
$0.00
Consensus
$0.00
+0.0% upside
Low
$0.00
Median: $0 · Last Close: $0.63
Short-Term Price Prediction
Algorithmically generated · Updated daily
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-10 | $0.64 | ↑ 1.46% |
1-day model range: $0.63–$0.64. Peak: $0.64 (+1.46%).
Long-Term Stock Price Prediction
Annual stock price forecast · 2027 / 2028 / 2029 / 2030 / 2031
| Year | Avg Price | Change |
|---|---|---|
| 2027 | $0 | -50.0% |
| 2028 | $0 | -62.5% |
| 2029 | $0 | -67.2% |
| 2030 | $0 | -69.2% |
| 2031 | — | -70.2% |
Stock Forecast Based on Technical Analysis
14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency
Market Sentiment
BULLISH
Based on 14 technical indicators
Refreshes daily from EOD close
Moving Averages · SESN · Jun 9, 2026
Latest Analyst Ratings & Upgrades
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2021-08-16 | HC Wainwright & Co. | Downgrade ↓ | Buy→Neutral |
| 2021-02-17 | Canaccord Genuity | Maintains | Buy→Buy |
| 2021-02-17 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2019-06-11 | H.C. Wainwright | Upgrade ↑ | Neutral→Buy |
| 2019-06-11 | HC Wainwright & Co. | Upgrade ↑ | Neutral→Buy |
| 2018-07-23 | Jefferies | Maintains | Buy→Buy |
| 2018-05-10 | Laidlaw & Co. | Maintains | Buy→Buy |
| 2018-03-20 | H.C. Wainwright | Maintains | Buy→Buy |
| 2016-03-16 | Citigroup | Maintains | Neutral→Neutral |
| 2016-01-19 | Leerink Swann | Downgrade ↓ | Outperform→Perform |
Wall Street analysts have recently issued updated ratings on Sesen Bio, Inc. (SESN) stock. Of the recent 13 rating actions, 2 were upgrades and 2 were downgrades. 8 analysts currently cover SESN.
Analyst Recommendation Trends
SESN analyst recommendation trends show decreasing buy-side sentiment over the past 6 months. Buy rating actions changed from 1 to 0 per month.
Financial Forecast: EPS & Revenue Estimates
Revenue This Year
$58M
Revenue Next Year
—
EPS This Year
$-0.83
EPS Next Year
—
EPS ForecastReported vs Estimated
Analysts forecast SESN EPS of $-0.83 for the current fiscal year, based on estimates from 14 analysts. The SESN revenue forecast is $58M for the current year. These are analyst consensus estimates via FMP / S&P Global.
About Forecast & Price Prediction
The SESN stock forecast is supported by two independent data sources: analyst consensus ratings from 8 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus SESN price target is $0.00 (+0.0% upside), with an analyst consensus of Buy.
The SESN short-term stock prediction for tomorrow is $0.64 (+1.46%). The SESN stock price prediction for 2027 estimates an average of $0. The SESN stock prediction for 2030 projects a range of $0–$0.
Sesen Bio, Inc. trades on NASDAQ under the ticker SESN. The SESN stock outlook for 2027 is broadly positive, supported by a Buy consensus among 63% of covering analysts.
Frequently asked questions
SESN forecast · 8 questionsAccording to 8 Wall Street analysts, the average 12-month SESN price target is $0.00, with a high forecast of $0.00 and a low of $0.00. The median price target is shown in the chart above when available. This implies +0.0% potential upside from the current price of $0.63.
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.